Redeye views Genovis’ Q3 as softer than anticipated. A cautious end-market sentiment and tough comparables resulted in negative organic growth and weaker profitability than expected. While the outlook for Q4 remains solid, we will make downward adjustments to our near-term estimates and fair value range.
LÄS MER
